C-RAD Wrote Off SEK 93 Million of Backlog — Then Unveiled a Platform Strategy in the Same Breath

A quarter that broke, sold as a foundation

C-RAD's third quarter of 2026 is the kind of print where the income statement and the strategy deck describe two different companies. The income statement says order intake of SEK 76 million, down 29% year-on-year, and revenue of SEK 85 million, down 24%. The strategy deck says the company is becoming an open workflow platform for cancer care. Both are true, and the gap between them is the story.

The regional split explains the miss cleanly enough. EMEA order intake fell 40% and APAC 34%, with revenue down 23% and 33% respectively, as product deliveries slipped. The single bright spot was the Americas, where order intake grew more than 20% only to see revenue fall 6% — the timing wedge between booking and delivery that management leans on hard. Tomas Blomquist did not sugarcoat the headline: “Q3 was a weaker quarter financially than we had expected.” — Tomas Blomquist, CEO · 2026-10-22

What held the P&L together was mix. Service revenue hit a record SEK 30 million, 35% of the quarter, lifting gross margin to 76% from 74% and keeping EBIT at SEK 10 million, a 12% margin. OpEx after capitalisation fell 7% to SEK 54 million on a headcount trim from 106 to 100. That is a genuinely defensive model — but it is also the model of a company living off an installed base of roughly 2,200 systems rather than selling new ones. The install base is now the earnings engine; product deliveries are the variable that keeps disappointing. Blomquist's own framing — “there is a tremendous slowdown in order bookings coming through” — Tomas Blomquist, CEO · 2026-10-22 — is as blunt as disclosure gets for a company that has historically preferred to talk about long cycles.

The SEK 93 million question

The number that deserves the most attention is not in the income statement at all. C-RAD wrote down SEK 93 million of order stock — larger than the quarter's entire revenue — after a review across all regions. The justification is that the orders were old and will not affect coming revenue. That is either excellent hygiene or an admission that a meaningful slice of the backlog was never going to convert, and the market has no way to distinguish between the two from the outside.

As part of our ongoing efforts to ensure a high-quality business, we conducted a thorough review across all regions during the quarter. This has resulted in a writedown of SEK 93 million of our order stock.

Pressed on whether the write-down related to a cancelled U.S. order and what lead times were involved, Linda Frölén declined to size the specific customer and said only that it spanned all regions and carried no P&L impact, adding there were no further orders at risk "at this point." Blomquist reframed the exercise as commercial conversion discipline — building a more scalable company by clearing out what will not ship. Investors should note the asymmetry: the same management team that tells you the backlog is now clean also declines to guide, so the backlog is simultaneously the reason to believe and an unaudited assertion.

The vocabulary has changed faster than the business

The most striking feature of this quarter's language is how completely the company's keyword centre of gravity moved. The fastest-rising terms are ecosystem, clinical workflow, identity verification, automation, and the partner name SeeTreat — alongside the flagship Catalyst and Sentinel products. That is a software-platform lexicon bolted onto a hardware franchise in the same quarter its core hardware business shrank by a quarter.

Eeva-Liisa Karjalainen, newly visible as Chief Product and Technology Officer, laid out a three-layer architecture: defend SGRT, extend into the radiotherapy workflow, then build outward via a build-partner-buy model. The first fruits are a patient identity verification product and an interoperability hook into United Imaging CT scanners. The company also disclosed that product development spend has risen about SEK 16 million annually over two years precisely because, in Frölén's words, past innovation pace "has not been where it needed to be." That is a rare, useful admission.

The commercial promise attached to it is modest and dated: “You will already see during 2027 some revenue and order intake coming into the group” — Tomas Blomquist, CEO · 2026-10-22. Note that this three-year transformation "began earlier this year" and the platform revenue lands in year two — meaning 2026 is a pure investment year against a shrinking base.

Guidance, cash, and the number that moved

Asked directly whether the target of revenue growth next year still holds given the headwinds, Blomquist delivered the answer that will define the next two quarters of sentiment: “We're not a guidance company.” — Tomas Blomquist, CEO · 2026-10-22 He then reaffirmed the mid-term targets and the 25% EBIT margin ambition without a path or a date. For a company whose entire investment case now rests on a multi-year platform build, refusing to anchor even the first year of the ramp leaves the equity priced on narrative.

Capital allocation is where the story gets mildly odd. Frölén reported cash of SEK 144 million at quarter end, up SEK 6 million in the quarter, with positive working capital flow of SEK 4 million. An analyst on the call referred to "SEK 177 million in cash" and was not corrected — a discrepancy worth resolving in the filing. Against that balance sheet sits a buyback of up to SEK 20 million, a standing dividend, and an explicit acquisition appetite. Blomquist was unambiguous that deals are live: “We are already in talks related to both those last components.” — Tomas Blomquist, CEO · 2026-10-22 A sub-scale medtech spending on software, buybacks, dividends and M&A simultaneously, while revenue declines 24%, is a capital allocation question, not a strategy question.

One genuine cross-market note: the Americas order growth lands in the same quarter the global keyword set surfaced Growth in Americas as a top-25 theme — a reminder that regional mix, not company-specific brilliance, is doing some of the work. And C-RAD is not alone in the capital-equipment order lurch; order intake and large-order lumpiness dominate this week's industrial and medtech prints, which is the more forgiving read. The less forgiving read is that a 25% EBIT margin target and a platform pivot both require the thing management just wrote down: a backlog that converts.